In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed the day trading at $12.20 down -3.10% from the previous closing price of $12.59. In other words, the price has decreased by -$3.10 from its previous closing price. On the day, 0.96 million shares were traded. DAWN stock price reached its highest trading level at $12.6201 during the session, while it also had its lowest trading level at $12.175.
Ratios:
For a better understanding of DAWN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 10 ’24 when Blackman Samuel C. sold 30,000 shares for $13.31 per share. The transaction valued at 399,339 led to the insider holds 1,034,015 shares of the business.
Bender Jeremy sold 10,554 shares of DAWN for $139,420 on Nov 18 ’24. The CHIEF EXECUTIVE OFFICER now owns 108,377 shares after completing the transaction at $13.21 per share. On Nov 18 ’24, another insider, Blackman Samuel C., who serves as the HEAD OF R&D of the company, sold 2,206 shares for $13.21 each. As a result, the insider received 29,142 and left with 1,064,015 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1269654016 and an Enterprise Value of 674556800. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.95 while its Price-to-Book (P/B) ratio in mrq is 2.21. Its current Enterprise Value per Revenue stands at 6.616 whereas that against EBITDA is -3.282.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.46, which has changed by -0.13112491 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $11.94. The 50-Day Moving Average of the stock is -11.06%, while the 200-Day Moving Average is calculated to be -14.58%.
Shares Statistics:
Over the past 3-months, DAWN traded about 1.09M shares per day on average, while over the past 10 days, DAWN traded about 928270 shares per day. A total of 100.81M shares are outstanding, with a floating share count of 72.64M. Insiders hold about 27.97% of the company’s shares, while institutions hold 81.28% stake in the company. Shares short for DAWN as of 1734048000 were 18097423 with a Short Ratio of 16.64, compared to 1731628800 on 18661330. Therefore, it implies a Short% of Shares Outstanding of 18097423 and a Short% of Float of 21.68.
